

# Law Offices of Albert Wai-Kit Chan, LLC

World Plaza, Suite 604, 141-07 20th Avenue • Whitestone, NY 11357 • USA  
Tel: (718) 357-8836 • Fax: (718) 357-8615 e-mail: kitchanlaw@aol.com

**FAX RECEIVED**

APR 8 2003

**GROUP 1600**

FACSIMILE TRANSMISSION  
PLEASE DELIVER THE FOLLOWING PAGES

TO : EXAMINER LARRY R. HELMS

COMPANY : UNITED STATES PATENT AND TRADEMARK OFFICE

FAX NO. : 703-308-4242

FROM : ALBERT WAI-KIT CHAN

DOCKET : SHAWN SHUI-ON LEUNG, U.S. PATENT APPLICATION  
FOR REDUCING IMMUNOGENICITIES OF  
IMMUNOGLOBULINS BY FRAMEWORK-PATCHING,  
U.S. SERIAL NO. 09/892,613, FILED ON JUNE 27, 2001 –  
DKT. #655

**OFFICIAL**

TOTAL NUMBER OF PAGES, INCLUDING COVER SHEET : 26

DATE : APRIL 7, 2003

\* IF YOU DO NOT RECEIVE ALL THE PAGES, PLEASE CALL BACK AS SOON AS  
POSSIBLE TO (718) 357-8836.

Message

Applicant: LEUNG, Shawn Shui-on  
Client: Shawn Shui-on LEUNG (344)  
Date: April 7, 2003

File No.: 655

**AMENDMENT IN RESPONSE TO JANUARY 7, 2003 OFFICE ACTION** for Shawn Shui-on LEUNG, for REDUCING IMMUNOGENICITIES OF IMMUNOGLOBULINS BY FRAMEWORK-PATCHING, U.S. Serial No. 09/892,613, Filed June 27, 2001.

THE INFORMATION CONTAINED IN THIS FACSIMILE TRANSMISSION IS INTENDED SOLELY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE DESIGNATED RECIPIENT(S) NAMED ABOVE. THIS TRANSMISSION MAY CONTAIN INFORMATION THAT IS CONFIDENTIAL UNDER THE CLIENT AND ATTORNEY RELATIONSHIP. IF THE READER OF THIS MESSAGE IS NOT A DESIGNATED RECIPIENT OR AN AGENT RESPONSIBLE FOR DELIVERING IT TO A DESIGNATED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS DOCUMENT IN ERROR, AND THAT ANY REVIEW, DISTRIBUTION, OR COPYING OF THIS MESSAGE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, OR IF UPON READING THIS DOCUMENT YOU HAVE REASON TO BELIEVE THAT THE DOCUMENT WAS INADVERTENTLY SENT TO YOU, PLEASE NOTIFY US IMMEDIATELY BY COLLECT TELEPHONE CALL AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.

Dkt. #655

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Shawn Shui-on LEUNG  
U.S. Serial No.: 09/892,613 Examiner: Larry Ronald Helms  
Filed : June 27, 2001 Art Unit: 1642  
For : REDUCING IMMUNOGENICITIES OF IMMUNOGLOBULINS  
BY FRAMEWORK-PATCHING

Law Offices of Albert Wai-Kit Chan, LLC  
World Plaza, Suite 604  
141-07 20<sup>th</sup> Avenue  
Whitestone, New York 11357

April 7, 2003

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir/Madam:

FACSIMILE CERTIFICATE  
IN CONNECTION WITH THE ABOVE-IDENTIFIED APPLICATION

I hereby certify that this paper is being sent on the date indicated above and is addressed to Assistant Commissioner for Patents, Washington, D.C. 20231.

\_\_\_\_\_  
Printed Name: Sheau Yi Lou

Respectfully submitted,

Albert Wai-Kit Chan  
Albert Wai-Kit Chan  
Registration No. 36,479  
Attorney for Applicants  
Law Offices of  
Albert Wai-Kit Chan, LLC  
World Plaza, Suite 604  
141-07 20<sup>th</sup> Avenue  
Whitestone, New York 11357  
Tel: (718) 357-8836  
Fax: (718) 357-8615  
e-mail: kitchanlaw@aol.com

Dkt. #655

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Shawn Shui-on LEUNG  
U.S. Serial No. : 09/892,613 Examiner: Larry Ronald Helms  
Filing Date : June 27, 2001 Art Unit: 1642  
For : REDUCING IMMUNOGENICITIES OF  
IMMUNOGLOBULINS BY FRAMEWORK-PATCHING

Law Offices of Albert Wai-Kit Chan, LLC  
World Plaza, Suite 604  
141-07 20<sup>th</sup> Avenue  
Whitestone, NY 11357

April 7, 2003

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

AMENDMENT RESPONSE TO  
THE JANUARY 7, 2003 OFFICE ACTION

This Amendment is submitted in response to the January 07, 2003 Office Action issued by the United States Patent and Trademark Office in connection with the above-identified application. A response to the January 7, 2003 Office Action is due April 7, 2003. Therefore, this Amendment is being timely filed.

Please amend the specification as follows:

In the Abstract, page 51

Please replace the Summary of the Abstract by the following Abstract:

RA  
--] Framework (FR)-patching is a novel approach to modify immunoglobulin for reducing potential immunogenicity without significant alterations in specificity and affinity. Unlike previously described methods of humanization, which graft CDRs from a donor onto the frameworks of a single acceptor immunoglobulin, we patch segments of framework (FR1, FR2, FR3,